Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Кафедра психиатрии и наркологии медицинского факультета Санкт-Петербургского государственного университета 2ФБГУ Федеральный центр сердца, крови и эндокринологии им. В.А.Алмазова 3Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М.Бехтерева
Список исп. литературыСкрыть список 1. Вакс В.В. Гиперпролактинемия: причины, клиника, диагностика и лечение. Cons. Med. 2001; 11 (3). 2. Вовин Р.Я. Клинические эффекты при психофармакологическом лечении. В монографии «Фармакотерапевтические основы реабилитации психически больных». М., 1989; с. 10–35. 3. Кинкулькина М.А. Депрессии при различных психических заболеваниях: клиника и лечение. Автореф. дис. … д-ра мед. наук, 2007. 4. Мазо Г.Э. Депрессивные нарушения в клинике эндогенных психозов (клинико-фармакотерапевтическое исследование). Автореф. дис. … д-ра мед. наук. М., 2005. 5. Мосолов С.Н., Миссионжник Э.Ю., Шаров А.И. и др. Применение дофаминстимулирующей терапии у больных эндогенными депрессиями. Соц. и клин. психиатрия. 1995; 4 (3): 76–81. 6. Addington D et al. Calgary depression scale for schizophrenia, 1993. 7. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiat 1989; 154: 672–6. 8. Bressan RA, Costa DC, Jones HM et al. Typical antipsychotic drugs – D2-receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res 2002; 56: 31–6. 9. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinol 2003; 28: 69–82. 10. Maggini C, Raballo A. Exploring depression in schizophrenia. Europ Psychiat 2006; 21: 227–32. 11. Crenshaw TL, Goldberg JP. Drugs that affect sexual functioning. London: sexual pharmacology, 1996 (Norton). Galactorrhea and hyperprolactinaemia. Med North Am 1990; 13: 1569–79. 12. Crismon MI, Dorson PG, Schizophrenia. In: J. Di Piro, R.Talbert, G.Yee et al. Pharmacotherapy: a pathophysiologic approach. 3rd ed. Appletonand Lange. Standord, CT. 1997; p. 1367–94. 13. De Alarcon R, Camey M. Severe depressive mood changes following slow-release intra-muscular fluphenazine injection. British Med J 1969; 3: 564–7. 14. Docherty NM. Affective reactivity of symptoms as a process discriminator in schizophrenia. J Nerv Ment Dis 1996; 184 (9): 53–4. 15. Fenton WS. Depression, suicide and suicide prevention in schizophrenia. Suicide and Life Threatening Behav 2000; 30: 34–49. 16. Floru L, Heinrich K et al. The problem of post-psychotic schizophrenic depression and their pharmacological induction. Int Pharmacopsychiat 1975; 10: 230–9. 17. Galdi J. The causality of depression in schizophrenia. Br J Psychiat 1983; 11: 621–5. 18. Guy W. NIMH. AIMS – Abnormal Involuntary Movement Scale. ECDEU assessment manual for psychopharmacology. Rockville, Maryland: National Institutes of Mental Health 1976; p. 534–7. 19. Hunt IM, Kapur N, Robinson J et al. National confidential inquiry into suicide and homicide by people with mental illness. J Psychiat Pract 2006; 12 (3): 139–47. 20. Kay SR, Lindenmayer JP. Outcome predictors in acute schizophrenia. Prospective significance of background and clinical dimensions. J Nervous Ment Disease 1987; 175: 152–60. 21. Kendler KS. Gender differences in the rates of exposure to stressful life events and sensitivity to their depressogenic effects. Ed.: K.Kendler, L.Thornton, C.Prescott. Am J Psychiat 2001; 158: 587–93. 22. Lambert PA. Depression etneuroleptiquesa action prolongie. J Acta Psychiat 1987; 4: 100–8. 23. Jäger M, Riedel M, Schmauß M. Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response Markus Jäger, Michael Riedel, Max Schmauß. Psychiat Research 2008; 158: 297–305. 24. Massimo S, Mauri C, Moliterno D et al. Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs. Schizophrenia Research 2008; 99: 7–12. 25. Muller MJ. The Calgary Depression Rating Scale for schizophrenia in a healthy control group. Psychometric properties and reference values. J Affect Disord 2005; 88: 69–74. 26. Mouret J, Lemoine O, Minuit MP. Paris. Acad Sci 1987; 305 (3): 301–6. 27. Müller MJ. Overlap between emotional blunting, depression, and extrapyramidal symptoms in schizophrenia. Schizophr Res 2002; 57: 307–9. 28. Muller P. Depressive syndrome in Vertaufschizophrenerpsychosen. Stuttgart: F.Enwe Verlad, 1981. 29. Oosthuizen P, Emsley RA, Roberts MC et al. Depressive symptoms at admission predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia. Schizophrenia Research 2001; 58: 247–52. 30. Resnick SG, Rosenheck RA, Lehman AF. An exploratory analysis of correlates of recovery. Psychiat Serv 2004; 55 (5): 540–7. 31. Shaw M, Bushe C, Wildgust H et al. Prolactin screening in a naturalistic cohort of outpatients with schizophrenia in UK. Europ Neuropsychopharmacol 2005; 15 (3): 484. 32. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiat Scand 1970; 212 (44): 11–9. 33. Siris S. Depression in schizophrenia: recognition and management in the USA. S.Siris. Schizophrenia Research 2001; 47 (2–3): 185–97. 34. Siris SG. Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull 1991; 17: 75–98. 35. Siris SG, Bench C. Depression and schizophrenia. In: S.Hirsch, D.Weinberger (Eds.). Schizophrenia, 2nd ed. Blackwell Science, Malden. Massachusetts, 2003; p. 142–67. 36. Tandon R, Halbreich U. The second-generation «atypical» antipsychotics: similar improved efficacy but different neuroendocrine side effects. Psychoneuroendocrinol 2003; 28 (1): 1–7. 37. Tapp A, Kilzieh N, Wood AE et al. Ed.: M.Raskind, R.Tandon. Depression in patients with schizophrenia during an acute psychotic episode. Comprehensive Psychiat 2001; 42: 314–8. 38. Van Putten T, May PR. «Akinetic depression» in schizophrenia. Arch Gen Psychiat 1978; 43: 1015–6. 39. Windgassen K, Wesselman U, Schulze MH. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiol 1996; 33: 142–6.